Stabilized hemagglutinin (HA) trimers as influenza vaccine antigens
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Oct 8, 2024
Grant Date -
N/A
app pub date -
May 22, 2024
filing date -
May 22, 2024
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully